Harbin Pharmaceutical Group Co Ltd (600664) — Cash Flow Quality Index
Harbin Pharmaceutical Group Co Ltd (600664) has a Cash Flow Quality Index of -2.79x as of September 2025. Operating cash flow of CN¥-192.19 Million is below net income of CN¥68.89 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore Harbin Pharmaceutical Group Co Ltd cash conversion from operations to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Harbin Pharmaceutical Group Co Ltd Cash Flow Quality Index (1998–2024)
Historical Cash Flow Quality Index for Harbin Pharmaceutical Group Co Ltd across 26 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 600664 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Harbin Pharmaceutical Group Co Ltd (1998–2024)
Year-by-year earnings quality comparison for Harbin Pharmaceutical Group Co Ltd. For live market cap and the full company financial profile, see Harbin Pharmaceutical Group Co Ltd stock valuation.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.15x | CN¥792.50 Million | CN¥690.61 Million | ▼ -52.2% |
| 2023 | 2.40x | CN¥949.67 Million | CN¥395.26 Million | ▲ +97.4% |
| 2022 | 1.22x | CN¥622.09 Million | CN¥511.09 Million | ▲ +407.1% |
| 2021 | -0.40x | CN¥-162.44 Million | CN¥409.85 Million | ▲ +83.0% |
| 2019 | -2.34x | CN¥-284.94 Million | CN¥121.87 Million | ▼ -236.2% |
| 2018 | 1.72x | CN¥692.72 Million | CN¥403.63 Million | ▲ +434.1% |
| 2017 | 0.32x | CN¥149.22 Million | CN¥464.36 Million | ▼ -90.2% |
| 2016 | 3.29x | CN¥2.78 Billion | CN¥843.80 Million | ▲ +21.9% |
| 2015 | 2.70x | CN¥1.66 Billion | CN¥614.48 Million | ▼ -53.0% |
| 2014 | 5.75x | CN¥1.14 Billion | CN¥197.68 Million | ▲ +454.0% |
| 2013 | 1.04x | CN¥141.64 Million | CN¥136.53 Million | ▲ +9.7% |
| 2012 | 0.95x | CN¥557.83 Million | CN¥590.03 Million | ▲ +1840.9% |
| 2011 | -0.05x | CN¥-31.56 Million | CN¥581.22 Million | ▼ -105.3% |
| 2010 | 1.02x | CN¥1.15 Billion | CN¥1.13 Billion | ▼ -48.7% |
| 2009 | 1.98x | CN¥1.85 Billion | CN¥933.59 Million | ▲ +196.0% |
| 2008 | 0.67x | CN¥578.59 Million | CN¥863.65 Million | ▼ -39.0% |
| 2007 | 1.10x | CN¥650.16 Million | CN¥592.25 Million | ▼ -14.5% |
| 2006 | 1.28x | CN¥738.08 Million | CN¥575.16 Million | ▼ -8.7% |
| 2005 | 1.41x | CN¥757.76 Million | CN¥538.90 Million | ▲ +157.5% |
| 2004 | 0.55x | CN¥149.01 Million | CN¥272.83 Million | ▼ -36.8% |
| 2003 | 0.86x | CN¥302.83 Million | CN¥350.57 Million | ▼ -30.0% |
| 2002 | 1.23x | CN¥383.44 Million | CN¥310.55 Million | ▼ -40.2% |
| 2001 | 2.07x | CN¥604.13 Million | CN¥292.44 Million | ▼ -12.6% |
| 2000 | 2.36x | CN¥541.70 Million | CN¥229.07 Million | ▼ -13.4% |
| 1999 | 2.73x | CN¥431.22 Million | CN¥157.91 Million | ▲ +64.4% |
| 1998 | 1.66x | CN¥221.41 Million | CN¥133.33 Million | — |